Latest Tax News

Hawsons Iron has confirmed a 69.3% Fe magnetite concentrate in bulk testwork and identified a possible second iron product from the processing waste stream. The gains arrive alongside a $1.23 million capital raise, but quarter-end cash covered only 1.22 quarters of reported outgoings before a later tax incentive receipt.

Skin Elements has converted its New Zealand Farmlands agreement into a first NZ$150,000 ECO-Nurture delivery, while A$900,000 in placement proceeds lifted quarter-end cash to A$1.455 million. The commercial progress comes alongside a cost review and a regulatory hurdle still standing between the company and broader national sales.

Boab Metals has emerged from FY26 with full ownership of Sorby Hills, construction underway and a larger reserve base, but the project’s crucial debt drawdown remains conditional. First concentrate is still targeted for the September quarter of 2027.

Black Bear Minerals has completed its first Shafter check-assay program, with re-tested historic intervals generally returning higher silver grades and previously overlooked gold mineralisation. The company is targeting a maiden JORC Mineral Resource Estimate in the fourth quarter while preparing underground drilling and carrying A$7.819 million in cash.

Red Hill Minerals collected A$6.0 million from its Onslow Iron royalty in the September quarter while maintaining A$58.7 million in cash after paying a fully franked dividend. Exploration also advanced across copper, gold and base metals, although several results remain early-stage and require further drilling.

Capricorn Metals has completed and commissioned the Karlawinda expansion, lifting the project to a targeted 6.5Mtpa throughput rate while maintaining FY27 production guidance. The company also reported A$113.1 million in quarterly operating cash flow, a larger resource base and federal approval for its next major growth project at Mt Gibson.

Great Boulder Resources has completed more than 57,000 metres of drilling across Peak Hill and Side Well during the September quarter, with high-grade results supporting potential resource growth. The ASX-listed explorer ended the period with A$12.3 million in cash and no debt as it works towards a Peak Hill resource update by year-end.

Immutep has identified structural differences between the efti used in its failed TACTI-004 Phase III trial and batches used in earlier successful studies, prompting a new 200 L manufacturing run. The biotech is narrowing efti’s future development focus while elevating autoimmune candidate IMP761 to co-priority status.

Freightways delivered double-digit growth across revenue and profit in FY26, but elevated fuel prices and weaker premium-service demand are now squeezing margins. The NZX and ASX-listed courier group expects volumes to remain subdued until fuel costs ease sustainably.

Cambium Bio has moved Elate Ocular into Phase 3 manufacturing and submitted an updated CAMOMILE-2 protocol to the FDA. The company is targeting First Patient In by year-end, but that timetable depends on a conditional A$7.1 million placement, unsigned CRO agreements and release of the first clinical batch.

Right Resources has moved its Blue gold-tungsten project from surface mapping to its first subsurface test, with assays due in the December quarter. The exploration milestone comes alongside a tighter funding position, with reported cash coverage of 1.90 quarters and further financing under consideration.

The Australian Takeovers Panel has declared unacceptable circumstances in A2MP Investments’ lapsed A$0.05-a-share takeover bid for Canyon Resources, citing inadequate disclosure, the use of confidential information and potential coercion of shareholders. Final orders remain undecided.